Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Yan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Current Biology : CB|May 21, 2026
Visual processing is a language-agnostic window into heterogeneity in early reading developmentMahalakshmi Ramamurthy, Klint Kanopka, Julian M Siebert, et al.
Clinical and Translational Science|March 6, 2026
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 InhibitorSimon J Shaw, Vanessa C Taylor, Jonathan T Sims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumorsMichael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Current Biology : CB|May 21, 2026
Visual processing is a language-agnostic window into heterogeneity in early reading developmentMahalakshmi Ramamurthy, Klint Kanopka, Julian M Siebert, et al.
Clinical and Translational Science|March 6, 2026
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 InhibitorSimon J Shaw, Vanessa C Taylor, Jonathan T Sims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumorsMichael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Pageof 2